Antonioli Alexandra H, White Janice, Crawford Frances, Renner Brandon, Marchbank Kevin J, Hannan Jonathan P, Thurman Joshua M, Marrack Philippa, Holers V Michael
Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045.
Howard Hughes Medical Institute, Denver, CO 80206.
J Immunol. 2018 Jan 1;200(1):316-326. doi: 10.4049/jimmunol.1602017. Epub 2017 Nov 29.
Factor H (FH) is a key alternative pathway regulator that controls complement activation both in the fluid phase and on specific cell surfaces, thus allowing the innate immune response to discriminate between self and foreign pathogens. However, the interrelationships between FH and a group of closely related molecules, designated the FH-related (FHR) proteins, are currently not well understood. Whereas some studies have suggested that human FHR proteins possess complement regulatory abilities, recent studies have shown that FHR proteins are potent deregulators. Furthermore, the roles of the FHR proteins have not been explored in any in vivo models of inflammatory disease. In this study, we report the cloning and expression of recombinant mouse FH and three FHR proteins (FHR proteins A-C). Results from functional assays show that FHR-A and FHR-B proteins antagonize the protective function of FH in sheep erythrocyte hemolytic assays and increase cell-surface C3b deposition on a mouse kidney proximal tubular cell line (TEC) and a human retinal pigment epithelial cell line (ARPE-19). We also report apparent values for the binding interaction of mouse C3d with mouse FH (3.85 μM), FHR-A (136 nM), FHR-B (546 nM), and FHR-C (1.04 μM), which directly correlate with results from functional assays. Collectively, our work suggests that similar to their human counterparts, a subset of mouse FHR proteins have an important modulatory role in complement activation. Further work is warranted to define the in vivo context-dependent roles of these proteins and determine whether FHR proteins are suitable therapeutic targets for the treatment of complement-driven diseases.
补体因子H(FH)是一种关键的替代途径调节因子,可在液相和特定细胞表面控制补体激活,从而使先天免疫反应能够区分自身和外来病原体。然而,目前对FH与一组密切相关的分子(称为FH相关(FHR)蛋白)之间的相互关系尚不清楚。尽管一些研究表明人类FHR蛋白具有补体调节能力,但最近的研究表明FHR蛋白是有效的失调因子。此外,尚未在任何炎症性疾病的体内模型中探索FHR蛋白的作用。在本研究中,我们报告了重组小鼠FH和三种FHR蛋白(FHR蛋白A-C)的克隆和表达。功能测定结果表明,FHR-A和FHR-B蛋白在绵羊红细胞溶血试验中拮抗FH的保护功能,并增加小鼠肾近端小管细胞系(TEC)和人视网膜色素上皮细胞系(ARPE-19)上的细胞表面C3b沉积。我们还报告了小鼠C3d与小鼠FH(3.85μM)、FHR-A(136 nM)、FHR-B(546 nM)和FHR-C(1.04μM)结合相互作用的表观 值,这与功能测定结果直接相关。总体而言,我们的工作表明,与人类对应物相似,一部分小鼠FHR蛋白在补体激活中具有重要的调节作用。有必要进一步开展工作,以确定这些蛋白在体内的上下文依赖性作用,并确定FHR蛋白是否是治疗补体驱动疾病的合适治疗靶点。